Lead Researcher Highlights Tisagenlecleucel Benefit in Younger Leukemia Patients
The CD19-targeted CAR T-cell therapy, tisagenlecleucel (Kymriah) demonstrated durable remissions in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).